New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The plant is scheduled to come on stream in September 2024
Subscribe To Our Newsletter & Stay Updated
